Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is Dynavax Technologies a Buy?

TheMotleyFool

0 0

Shares of the small-cap biotech Dynavax Technologies (NASDAQ: DVAX) gained a stately 48% over the course of August, according to data from S&P Global Market Intelligence. What event sparked this sizable uptick?

On Aug. 7, the stock began churning higher in response to the company's second-quarter earnings report. Even though Dynavax reported a staggering $42.7 million net loss for the three-month period, investors were apparently more concerned about the current state of Heplisav-B's ongoing commercial launch. Heplisav-B is a vaccine approved by the Food and Drug Administration as a preventative treatment for hepatitis B. It is also the company's only FDA-approved product.

Image source: Getty Images.

Source Fool.com

Like: 0

DVAX

Share